414 results about "Drug concentration" patented technology

The invention discloses a method for in vitro slow release performance evaluation of a slow and controlled release preparation based on the overflow principle. A container with an upper outlet and a lower outlet is adopted to serve as a release tank, a to-be-detected medicine and a dissolution medium are placed in the release tank, a stirring device is adopted in the release tank to perform stirring, and the dissolution medium is added from the lower outlet of the release tank through a peristaltic pump; the dissolution medium dissolved with the medicine is taken away through the overflow from the upper outlet so as to offset medicine absorption or metabolism, and the slow and controlled release speed of the medicine, the total medicine overflow quantity and the total release amount are calculated by measuring the concentration of the medicine contained in the dissolution medium flowing out, the volume of the release tank and the overflow quantity. According to the method, the releasing degree of the slow and controlled release medicine can be evaluated accurately, the effective medicine release time of the slow and controlled release preparation is evaluated, and slow release performances of the slow and controlled release preparation are evaluated comprehensively.

The invention relates to the technical field of pharmaceutical preparations, and provides a minoxidil film coating agent as well as a preparation method and application thereof. The minoxidil film coating agent provided by the invention comprises 40-60% of propylene glycol, 3-7% of polyvinyl alcohol, 20-30% of ethanol, 1-7% of minoxidil and the balance of water. According to the invention, propylene glycol is taken as a solvent, a plasticizer and a transdermal absorption enhancer, polyvinyl alcohol is taken as a film-forming material, and ethanol is taken as a volatile agent, after administration, ethanol is volatilized to promote film formation of polyvinyl alcohol, and propylene glycol enhances the plasticity of the formed film, so that the effect of reducing liquid medicine loss is achieved, the local medicine concentration is increased, and the bioavailability is improved. The minoxidil liniment disclosed by the invention has excellent skin permeability, can effectively convey a medicine to a required part, and can ensure that the medicine is released at a fixed position of the skin and is accurately administered in a medicine release process, so that the stimulation of liquid medicine flow to other parts is reduced, and a good treatment effect is achieved.

The invention discloses an administration agent in-vivo release and absorption visualization method based on a CFD-PBM coupling model. The method comprises the following steps: constructing a CFD model of a physiological environment of an injection site; establishing a population balance model (PBM) of the drug particles; the PBM is embedded into a CFD model solver, multi-scale coupling simulation is carried out, and a CFD-PBM coupling model is obtained; the three-dimensional visualization engine dynamically displays drug concentration distribution and particle behaviors; reversely adjusting preparation prescription parameters by using a multi-parameter optimization algorithm; and calibrating model parameters, and generating a key data report. According to the method, the prediction precision and the research and development efficiency can be remarkably improved, and the method is suitable for development of long-acting preparations such as microspheres and implants.

The invention provides a micro-fluidic chip capable of culturing oral squamous cell carcinoma organoid and a preparation method thereof, and relates to the technical field of micro-fluidic chips, the chip comprises a four-layer structure: the first layer is a closed layer, the second layer is a culture solution / drug pool layer (containing a concentration gradient injection channel and a slow flow channel), the third layer is a matrix culture pool layer, and the fourth layer is a matrix culture pool layer. The fourth layer is a matrigel inflow layer (containing an S-shaped flow channel); the second layer and the third layer are integrally formed, and all the layers are connected through oxygen plasma welding; the problems that in the prior art, matrigel is prone to shifting, drug gradient regulation and control is poor, operation is tedious, and adaptability is insufficient are solved, the matrigel and organoids can be stably fixed, the drug concentration gradient can be precisely regulated and controlled, the nutrition supply efficiency is enhanced, the structural integration level and operation convenience are improved, and the application prospect is wide. The method is suitable for oral squamous cell carcinoma organoid culture, drug screening and tumor mechanism research.

The invention discloses an SERS (Surface Enhanced Raman Scattering) detection method for paclitaxel drug concentration in blood of a breast cancer patient, and belongs to the technical field of detection. The method comprises the following steps: performing acetonitrile two-step precipitation centrifugal treatment on a blood sample to obtain a detection sample; the method comprises the following steps: constructing a high-sensitivity SERS substrate (the volume ratio of gold nanoparticles to ethanol is 1: (90-100), and a film is formed on a water-cyclohexane interface) through self-assembly of gold nanoparticles on a liquid-liquid interface; the method comprises the following steps: dropwise adding a sample into a substrate, and detecting characteristic peaks of 1024cm <-1 > and 1053cm <-1 > by using a portable Raman spectrometer (785nm, 30mW, 0.5 s); and calculating the paclitaxel concentration in combination with a pre-established quantitative curve. The method is easy and convenient to operate and suitable for clinical bedside rapid monitoring.

The invention relates to the technical field of blood concentration detection by optical means, in particular to a clinical blood concentration detection method. The method comprises the following steps: acquiring the delay responsivity of spectral data to drug concentration and the change complexity of other wavebands except a preset characteristic waveband; further obtaining the interfered change credibility of the drug concentration; according to the morphological characteristics of the spectrum curve corresponding to each drug concentration in the preset characteristic wave band and the distribution difference characteristics of the data points between the corresponding spectrum curve and the preset spectrum curve in the preset characteristic wave band, obtaining the spectrum shape distortion of the spectrum curve corresponding to each drug concentration in the preset characteristic wave band; obtaining the processing beneficial confidence of the spectral data; filtering the spectral data to obtain filtered spectral data; and detecting the blood concentration. According to the method, interference components in spectrum detection are removed, so that the quality of spectrum data and the detection precision of the blood concentration are improved.

The application discloses a bacteriostatic and acne-removing microemulsion containing plant extracts and a preparation method thereof. The bacteriostatic and acne-removing microemulsion contains a microemulsion loaded with quercetin alone, a microemulsion loaded with sasanquasapernin alone, and a microemulsion loaded with quercetin and sasanquasapernin simultaneously. The bacteriostatic and acne-removing microemulsion containing plant extracts prepared by the application not only solves the problems of stickiness of camellia oil and poor solubility of quercetin, but also has a synergistic inhibitory effect on propionibacterium acnes, achieves the same high-efficiency bacteriostatic effect with a lower drug concentration, saves drug cost, reduces drug irritation, and expands the application of quercetin and sasanquasapernin in the cosmetic and pharmaceutical fields due to the rich pharmacological effect of the plant extracts, low side effect and safety. The microemulsion system prepared by the application is clear, transparent, uniform and stable, the preparation process is simple, the required energy is low, the cost is low, and the system is beneficial to commercial production.

The invention discloses a capsule medicament for endoscopic treatment of ulcerative colitis and a preparation method thereof, and belongs to the technical field of biological medicine, the capsule medicament is composed of a capsule matrix and a drug matrix; by adopting a dual control mechanism of an enteric layer coating and a pH response layer coating, accurate release of a medicine at a colon diseased region is ensured, medicine waste of the stomach and the small intestine is reduced, the medicine concentration at a focus is improved, mesalazine or budesonide is combined with the composite composition for treatment, inflammatory response is rapidly inhibited, acute symptoms are controlled, and the curative effect is good. A multi-mechanism synergistic treatment mode is adopted, the anti-inflammatory and repairing effects are enhanced, the clinical remission rate and the mucous membrane healing rate are remarkably improved, the pH response layer is dissolved in a colon alkaline environment, and the MMP-9 peptide cross-linking agent is subjected to enzymolysis at an inflammation part, so that the medicine is continuously released at a focus, the administration frequency is reduced, the compliance of a patient is improved, and the curative effect is good. In addition, the spherical gel particles in the medicament can prevent the medicament from being disintegrated too early in the intestinal tract, and the long-acting effect can be maintained.

The invention provides a stem cell exosome for overexpressing A beta degrading enzyme as well as a preparation method and application of the stem cell exosome. Specifically, the invention provides an application of the stem cell exosome overexpressing A beta degrading enzyme in preparation of drugs, and the drugs are used for at least one of the following: prevention, improvement or treatment of cognitive impairment related diseases; neuronal cell damage is improved; wherein the stem cells for overexpressing the A beta degrading enzyme are prepared through lentivirus transfection. According to the stem cell exosome overexpressing the A beta degrading enzyme, the content of the A beta degrading enzyme is obviously higher than that of the exosome prepared by a traditional method. Therefore, when the compound is prepared into a medicine for treating or preventing cognitive impairment related diseases, the medicine can be efficiently conveyed to the brain, and the concentration of the medicine in the brain is remarkably improved, so that the curative effect is enhanced, the dosage of the medicine can be reduced, the side effect is reduced, and the prognosis of brain diseases is effectively improved.

The invention discloses a drug targeted delivery device and method, and belongs to the technical field of intelligent medical treatment. The device comprises the following modules: an intelligent targeted recognition module for accurately recognizing a gastric cancer specific molecular marker and improving the selectivity and specificity of targeted recognition in combination with a dynamic surface modification strategy; the microenvironment real-time monitoring module is used for monitoring key physiological parameters of the gastric cancer microenvironment in real time; the intelligent path planning module is used for dynamically calculating and optimizing a drug delivery path and realizing accurate drug positioning; the personalized drug administration regulation and control module is used for accurately predicting the drug dosage demand of an individual and dynamically and finely adjusting the drug administration amount in real time; the drug resistance risk management module is used for early warning a drug resistance risk in advance and automatically generating a personalized alternative drug administration strategy through multi-dimensional drug resistance analysis and real-time early warning; and the intelligent drug release module adopts a temperature-sensitive / pH-sensitive polymer shell layer and a nano valve to control drug release, so that precise gradient release of drug concentration is realized.

The invention relates to the field of drug concentration detection, in particular to a rapid tacrolimus drug concentration detection device based on a micro-fluidic chip. The detection device comprises a blood sampling area, a separation area, a liquid medicine storage area, a waste liquid storage area and a spectrograph, the separation area is used for separating a tacrolimus medicine in a blood sample solution, and a liquid medicine sample and a waste liquid sample are obtained; the spectrograph is used for collecting liquid medicine spectral data of the liquid medicine sample in the liquid medicine storage area and waste liquid spectral data of the waste liquid sample in the waste liquid storage area, and detecting the concentration of the tacrolimus medicine in the blood sample solution according to the liquid medicine spectral data and the waste liquid spectral data. According to the invention, the accuracy of detecting the concentration of the tacrolimus drug in the blood can be improved.

The invention provides an airway atomization flow intelligent drug delivery control method and system, and relates to the technical field of medical instruments.The method comprises the steps that basic information of the age, the weight and the illness state severity of a patient is obtained, and physiological parameters of the respiratory rate and the tidal volume of the patient are collected in real time through a sensor; inputting the basic information and the physiological parameters into a fuzzy adaptive control algorithm, and initializing an individual administration rule base according to the basic information; based on the real-time change trend of the respiratory rate and the tidal volume, three initial control index values including an atomization flow value, a drug concentration value and a time interval are dynamically generated through a membership function. According to the invention, through the full-process design of data acquisition, intelligent modeling, accurate execution and data closed loop, intelligentization of atomization treatment is realized.

The invention relates to the technical field of medical instruments, in particular to an inhalation device for monitoring drug concentration in real time and a dose regulation and control method.The inhalation device comprises a bottom plate and a dry powder storage tank installed on the bottom plate, a fixing block is installed at the top end of the dry powder storage tank, and an inhalation pipe connected into the dry powder storage tank is embedded into the fixing block; a gas storage tank is installed on one side of the top end of the bottom plate, a connecting pipeline is connected between the gas storage tank and the dry powder storage tank, a gas inlet pipe connected to the rear end of the suction pipe is embedded in the top end of the gas storage tank, and a gas pump is installed on the side, close to the fixing block, of the top end of the dry powder storage tank. The air guide pipe is connected to a flow dividing pipe at the inner end of the fixing block, a plurality of injection pipes extending to the inner pipe wall of the suction pipe are embedded in the flow dividing pipe, an air bag cavity is formed in the suction pipe, and a plurality of reinforcing ribs are fixedly connected to the inner end of the air bag cavity. The pipe diameter of the suction pipe is enlarged, and concentration is reduced.

The invention belongs to the technical field of medical materials and medicine, and discloses a microneedle patch for accelerating oral mucosa wound healing and a method and application thereof, and the specific preparation method comprises the following steps: (1) preparing a substrate material; (2) preparing a photoactive initiator; (3) loading HS-38 on methacrylated gelatin; and (4) manufacturing a microneedle to obtain the HS-38 loaded microneedle patch for accelerating oral mucosa wound healing. The preparation process of the microneedle patch does not need to depend on expensive instruments and equipment, operation is easy and convenient, and the microneedle patch has the advantages of being accurate in local delivery, noninvasive and painless, controllable in local drug concentration, stable in local drug concentration and the like. The strategy not only provides an effective means for treating chronic oral wounds, but also lays a foundation for realizing clinical transformation and application of medicines, and has wide popularization and application prospects.

The invention belongs to the field of antibiotic analysis and detection, and discloses a quinolone drug SERS (Surface Enhanced Raman Scattering) detection method based on an improved silver nano-substrate and a spectral angle matching model. An improved Lee-Meisel method is adopted to synthesize silver nano sol with precisely controlled particle size, molecular adsorption is realized by utilizing electrostatic interaction of a positively charged quinolone drug and negatively charged silver nano particles, and a high-density Raman enhanced hot spot is formed after an agglomeration agent is added; the SERS spectrum is collected at the excitation wavelength of 785 nm and the integral time of 10 s, qualitative distinguishing of drugs is achieved by combining a spectrum angle matching model, and quantitative detection is achieved by constructing a standard curve through the linear relation between the characteristic peak intensity and the drug concentration logarithm. The detection limit of the four drugs is as low as 1.03-1.16 ppb, the classification accuracy rate reaches 100%, the method is obviously superior to existing similar methods, the detection matrix range is wide, such as animal food and dairy products, and universality and high sensitivity are both considered.

The invention relates to the technical field of manufacturing of medical instruments, in particular to an intracranial controllable drug balloon dilatation catheter and a drug delivery method for a narrow area of a blood vessel. According to the intracranial controllable medicine balloon dilatation catheter, the inner-layer catheter body is arranged in the outer-layer catheter body in a sleeved mode and fixedly connected with the far end of the outer-layer catheter body; the balloon is assembled on the outer-layer tube body and is provided with a plurality of dosing holes along the circumferential direction; a medicine adhesion layer is compounded on the surface of the balloon section of the outer-layer tube body; the stress releasing pipe is connected to the end, close to the operation end, of the outer-layer pipe body. The Y-shaped tube base is connected to the end, away from the outer-layer tube body, of the stress releasing tube, one connector is connected with an injection device to inject medicine carriers into the balloon, and the other connector is used for a guide wire to penetrate through. When intracranial vascular stenosis is treated, directional drug release can be achieved by means of the drug delivery holes and the drug adhesion layer. The medicine is sprayed to the focus through the administration hole, the medicine is promoted to permeate into the middle layer of the blood vessel wall through the attaching force generated by the balloon expansion, the problems of non-uniform liquid medicine distribution, insufficient permeation and the like are effectively solved, and the local medicine concentration and the treatment effect are improved.

The application discloses a kind of intelligent optical genetic and microdosing spatiotemporal coordination measurement and control system based on catheter assembly, belong to biomedical engineering and automatic control cross technical field.The system obtains optical power spatial distribution model by intelligent optical genetic module, obtains drug concentration distribution model and carries out fluid back pressure monitoring and prevents blocking by microdosing module, then maximum coincidence space is calculated by spatiotemporal coordination optimization module and space relative coordinate deviation instruction is generated, finally, through catheter assembly execution module, instruction is responded to adaptively adjust the physical spacing of light guide and dosing channel.The advantage of the application is that the defects of light medicine dispersion field mislocation and microtubule easy blockage in the prior art can be effectively solved, and high-precision in-vivo light medicine collaborative intervention is realized.

This invention provides ozenafloxacin nanocrystalline particles, its preparation method, and its uses. The preparation method includes the following steps: dissolving ozenafloxacin raw material in an acidic aqueous solution, then adding a stabilizer, stirring, and adjusting the pH to 4-6; wherein the stabilizer is a siloxane and / or a cellulose derivative. The preparation method provided by this invention can obtain ozenafloxacin nanocrystalline particles with uniform and stable particle size distribution. Further research by the inventors has found that formulations containing these ozenafloxacin nanocrystalline particles can increase the amount of drug retained in the skin, thereby increasing the local drug concentration, achieving effective killing of Propionibacterium acnes, and preventing the development of drug resistance.

The present invention discloses a PLGA-minoxidil microneedle with near-infrared response and a preparation method thereof. The PLGA-minoxidil microneedle with near-infrared response comprises: PLGA-minoxidil microspheres, lanthanum hexaboride nanoparticles, a matrix, and a needle body; wherein the PLGA-minoxidil microspheres and lanthanum hexaboride nanoparticles are distributed in the needle body; and the materials of the matrix and the needle body are a combination of PVA 1788 and PVA 1799. The present invention combines PLGA-minoxidil microspheres with hydrogel microneedles with near-infrared response. In terms of microstructure, the microporous structure of the microspheres and the near-infrared response of the lanthanum hexaboride nanoparticles cooperate to achieve controlled release of MXD, effectively reduce the side effects of the drug, better maintain the drug concentration in the body, and achieve better therapeutic effects. Macroscopically, the prepared hydrogel system has good mechanical properties and can provide a stable drug delivery channel and drug delivery efficiency.

The invention provides a mesenchymal stem cell composition as well as a preparation method and application thereof in knee joint products, and belongs to the technical field of medicines. The invention relates to application of a mesenchymal stem cell combined naringin derivative in preparation of medicines for treating osteoporosis and repairing knee joint injury and arthritis. The naringin derivative is prepared from naringin through an ether esterification reaction, the metabolic cycle of the naringin derivative is prolonged and the water solubility is improved while the original activity is maintained, so that the free drug concentration and tissue infiltration capacity in bones are improved, the bioavailability of the naringin derivative is improved, and the bioavailability of the naringin derivative is improved. The prepared mesenchymal stem cell composition can induce mesenchymal stem cell osteogenic differentiation and improve bone repair capacity, has a good intervention effect on osteoporosis, has a sustained and controlled release effect and prolongs medicinal time.

The invention discloses a traditional Chinese medicine composition for treating hyperthyroidism and a preparation method thereof, and relates to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition for treating hyperthyroidism is prepared from cyclodextrin grafted modified hollow mesoporous organic silicon nanoparticles, traditional Chinese medicine ferment powder and a traditional Chinese medicine extracting solution, the cyclodextrin-grafted modified hollow mesoporous organic silicon nano-particles are used as a carrier, traditional Chinese medicine ferment powder and a traditional Chinese medicine extracting solution are loaded, the medicine concentration of a focus part is increased, traditional Chinese medicine ingredients are rapidly released through rapid response fracture of tetrasulfide bond functional groups, and the traditional Chinese medicine composition is prepared in an active targeting and fixed-point blasting mode. The bioavailability and the onset time of the medicine are improved, the leakage risk of the medicine is jointly reduced through the gating effect of cyclodextrin and responsive release of tetrasulfide bonds, synthesis of thyroid hormone is more thoroughly inhibited under the precise effect of high-concentration medicine and multi-target immunoregulation of traditional Chinese medicine, and the recurrence rate of hyperthyroidism is reduced.

The application discloses a high-affinity rabbit monoclonal antibody against dupilumab and an application thereof, and relates to the technical field of monoclonal antibody preparation.The high-affinity rabbit monoclonal antibody provided by the application is a first antibody or a second antibody;the amino acid sequence of the heavy chain of the first antibody is shown in SEQ ID NO.8, and the amino acid sequence of the light chain is shown in SEQ ID NO.9;the amino acid sequence of the heavy chain of the second antibody is shown in SEQ ID NO.17, and the amino acid sequence of the light chain is shown in SEQ ID NO.18.The application also provides nucleic acid molecules for encoding the rabbit monoclonal antibody, a recombinant strain and other biological materials, and a drug and a product for detecting dupilumab.The rabbit monoclonal antibody provided by the application has high affinity, detection sensitivity and specificity for dupilumab, and can be used for diagnosing the total drug concentration and free drug concentration of dupilumab (DUPILUMAB) in the body of an injected patient; and has no cross reaction with human IgG4 and human total IgG. Dupilumab ) in the body of an injected patient; and has no cross reaction with human IgG4 and human total IgG.

Adaptive on board estimation of exogenous pharmacon responsive to transient (i.e., impermanent) physiological effects is provided. Dynamically estimating an equivalent amount of an exogenous pharmacon on board (XOB), such as insulin and / or carbohydrates, left in the subject, is based on predictions of glucose time-series data. These estimated values, such as insulin on board (IOB), are useful for diabetes management software, including decision support and / or artificial pancreas (AP) algorithms, for example.

This medication management device comprises an acquisition unit, a storage unit, and a control unit. The acquisition unit acquires drug administration information including an administration amount and an administration time of a drug for a patient. The storage unit stores past drug administration information of the patient as drug administration history information. The control unit estimates an in-vivo drug concentration of the patient on the basis of the drug administration history information, and executes, on the basis of the estimated in-vivo drug concentration of the patient, a process determined from a plurality of different processes.

The patent document discloses a dosage form featuring a unique combination of extended-release and immediate-release components of the active ingredient. This dosage form allows for high drug loading, enabling once-daily administration while providing a sustained window of effective treatment with reduced fluctuations in drug concentration. The document also discloses a method for treating neurological or psychiatric diseases or conditions in a subject.

The invention discloses a protein drug loaded GelMA microsphere, a preparation method and application thereof, the protein drug loaded GelMA microsphere comprises a GelMA microsphere and a protein drug loaded on the GelMA microsphere, and the protein drug is composed of albumin paclitaxel and alphaPD-L1. The drug carrier is loaded with albumin paclitaxel and the alphaPD-L1 antibody, so that synergistic treatment can be realized, and the cancer treatment effect is improved; gelMA is used as a drug carrier, albumin paclitaxel and an alphaPD-L1 antibody are delivered, and the drug-loaded GelMA microspheres are injected into tumor tissues in situ, so that the targeting property and bioavailability of the drug can be effectively improved, side effects are reduced, the drug is enriched in a focus, and the circulating drug concentration is reduced.

An example system for detecting and quantifying drug and / or chemical interactions with a biological sample is provided. The system includes a detection instrument with computing capability. The system includes an assay device capable of receiving a biological sample. Introduction of the biological sample into the assay device results in a biological process by which fibrin and platelets may accumulate at a reaction zone of the assay device. The assay device is capable of receiving one or more chemical reagents and one or more drug reagents. The fibrin and platelets, and their associated signals, accumulated at the reaction zone of the assay device are usable to determine at least one of a drug presence, a drug class, a drug level in relation to a threshold, or a drug concentration, within the biological sample.

The invention relates to a riociguat prodrug as shown in a formula X or pharmaceutically acceptable salt thereof, a preparation method, an intermediate and a pharmaceutical composition thereof. The prodrug takes amino of riociguat as a modification site and is connected through an ester carrier, drug release is triggered by utilizing lung amidase, and lung targeted delivery is realized by adjusting a lipid-water partition coefficient. Pharmacokinetic studies show that the prodrug can significantly improve the drug concentration and total exposure of the lung, reduce the blood concentration of the whole body, and show excellent lung targeting characteristics. The invention also provides a pharmaceutical composition (preferably an inhalation preparation) containing the prodrug, and an application of the prodrug in preparation of drugs for preventing, treating, treating or relieving pulmonary arterial hypertension of patients. .

This invention discloses a method and system for evaluating the effectiveness of cardiac rehabilitation, relating to the field of medical and health technology. The method includes: acquiring physiological monitoring data, individualized parameter data, comorbidity data, multidrug therapy data, pharmacokinetic parameters, and pharmacodynamic interaction parameters of the target patient; generating baseline physiological index data without drug intervention based on the individualized parameter data and comorbidity data through a pre-set individualized cardiac response baseline model; calculating drug concentration based on multidrug therapy data and pharmacokinetic parameters; calculating comprehensive pharmacodynamic data by combining pharmacodynamic interaction parameters; generating predicted physiological data under multidrug intervention; subsequently obtaining purified physiological data through adaptive filtering and frequency domain decomposition; and finally generating a rehabilitation effect score through a pre-trained long short-term memory network model. Its beneficial effects include: distinguishing between drug interference and real cardiac function improvement, and improving the accuracy of rehabilitation assessment for patients undergoing multidrug therapy.

The application discloses a kind of deuterated benzamide diazepine compounds and preparation method and purposes thereof, and structure is as shown in general formula I.The compound is used as selective OX2R antagonist, and shows good activity, selectivity, brain exposure, brain blood ratio (the ratio of drug concentration in brain and drug concentration in blood, is called B / P), little toxic side effect, moderate half-life effect etc..It can be used for preventing, treating and / or reducing the disease related to orexin receptor.General formula I